Tech Company Financing Transactions

SwanBio Therapeutics Funding Round

Mass General Brigham Innovation and Syncona participated in a $56 million Series B funding round for SwanBio Therapeutics. The financing round was announced on 5/19/2022.

Transaction Overview

Company Name
SwanBio Therapeutics
Announced On
5/19/2022
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series B
Investors

Mass General Brigham Innovation (Lead Investor)

Syncona (Lead Investor) (Chris Hollowood)

Proceeds Purpose
The company intends to use the funds for ongoing evolution into a fully integrated research and development organization, with an initial focus on the clinical advancement of SBT101, including plans to dose patients in a Phase 1/2 trial by the end of this year.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Monument Rd. 207
Bala Cynwyd, PA 19004
USA
Phone
Undisclosed
Website
www.swanbiotx.com
Email Address
[email protected]
Overview
SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is born of curiosity, collaboration, and compassion.
Profile
SwanBio Therapeutics LinkedIn Company Profile
Social Media
SwanBio Therapeutics Company Twitter Account
Company News
SwanBio Therapeutics News
Facebook
SwanBio Therapeutics on Facebook
YouTube
SwanBio Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Thomas Anderson
  Thomas Anderson LinkedIn Profile  Thomas Anderson Twitter Account  Thomas Anderson News  Thomas Anderson on Facebook
Chief Scientific Officer
Karen Kozarsky
  Karen Kozarsky LinkedIn Profile  Karen Kozarsky Twitter Account  Karen Kozarsky News  Karen Kozarsky on Facebook
Chief Technical Officer
Rebecca Dabora
  Rebecca Dabora LinkedIn Profile  Rebecca Dabora Twitter Account  Rebecca Dabora News  Rebecca Dabora on Facebook
Co-Founder
Florian Eichler
  Florian Eichler LinkedIn Profile  Florian Eichler Twitter Account  Florian Eichler News  Florian Eichler on Facebook
President
Rachel Salzman
  Rachel Salzman LinkedIn Profile  Rachel Salzman Twitter Account  Rachel Salzman News  Rachel Salzman on Facebook
VP - General Counsel
Michael Alexander
  Michael Alexander LinkedIn Profile  Michael Alexander Twitter Account  Michael Alexander News  Michael Alexander on Facebook
VP - Human Resources
Carolyn Carroll
  Carolyn Carroll LinkedIn Profile  Carolyn Carroll Twitter Account  Carolyn Carroll News  Carolyn Carroll on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/19/2022: Azra Games venture capital transaction
Next: 5/19/2022: Pressto venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to document funding rounds that are announced publicly. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.